EUVIMEDEUVIMED entdecken
Crossref

76863 Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials

Srinivas Sidgiddi, Linda Stein Gold, Richard Gallo, Sunil Dhawan, Shraddha Bayar, Srinivas Sidgiddi

Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB192

DOI: 10.1016/j.jaad.2026.04.783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Srinivas Sidgiddi und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Sidgiddi, S., Gold, L. S., Gallo, R., Dhawan, S., Bayar, S., & Sidgiddi, S. (2026). 76863 Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials. Journal of the American Academy of Dermatology, 95(1), AB192. https://doi.org/10.1016/j.jaad.2026.04.783

Vancouver

Sidgiddi S, Gold LS, Gallo R, Dhawan S, Bayar S, Sidgiddi S. 76863 Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials. Journal of the American Academy of Dermatology. 2026;95(1):AB192. doi:10.1016/j.jaad.2026.04.783

BibTeX
@article{Sidgiddi2026,
  author = {Sidgiddi, Srinivas and Gold, Linda Stein and Gallo, Richard and Dhawan, Sunil and Bayar, Shraddha and Sidgiddi, Srinivas},
  title = {76863 Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  volume = {95},
  number = {1},
  pages = {AB192},
  doi = {10.1016/j.jaad.2026.04.783}
}
Kostenlos starten →